Srikanth Kasula, MD
Interventional Cardiology · Davenport, IANPI 1497080709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,730 of the $43,445 with a category attached, or 79.9%. Johnson & Johnson accounts for 87.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $27,064 and has fallen 95.8% since, to $1,150 in 2025. Among interventional cardiology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $232.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$38K
- Inari Medical, Inc.$1K
- Edwards Lifesciences$1K
- Abbott$896
- Medtronic$290
- Philips North America LLC$251
- plus $1K from 17 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$34,73080%
- Travel & lodging$2,8887%
- Food & beverage$5,32812%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 58 | $38,208 |
| Inari Medical, Inc. | 23 | $1,372 |
| Edwards Lifesciences | 15 | $1,280 |
| Abbott | 44 | $896 |
| Medtronic(2 entities) | 4 | $290 |
| Philips North America LLC | 3 | $251 |
| Shockwave Medical, Inc | 9 | $212 |
| Astellas Pharma US Inc | 2 | $200 |
| Abiomed | 5 | $148 |
| United Therapeutics Corporation | 1 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $102 |
| Ablative Solutions, Inc. | 1 | $77 |
| Boston Scientific | 3 | $62 |
| Cordis US CORP. | 3 | $53 |
| Cook Medical LLC | 2 | $33 |
| Heartflow, Inc. | 1 | $28 |
| Bard Peripheral Vascular, Inc. | 2 | $27 |
| Surmodics, Inc. | 2 | $26 |
| Cardiva Medical, Inc. | 1 | $21 |
| Stryker | 1 | $18 |
| Biosense Webster, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $12 |
| Penumbra, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,445 in reported general payments places this provider in the 90th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 466 | $475,405 |
| XareltoRivaroxaban | 404 | $405,710 |
| EntrestoSacubitril/Valsartan | 147 | $165,400 |
| BrilintaTicagrelor | 165 | $117,059 |
| JardianceEmpagliflozin | 59 | $56,372 |
| Metoprolol Succinate | 1,292 | $14,664 |
| MultaqDronedarone Hcl | 12 | $12,118 |
| ClopidogrelClopidogrel Bisulfate | 777 | $6,076 |
| Atorvastatin Calcium | 824 | $5,927 |
| Prasugrel Hcl | 17 | $4,880 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $4,698 |
| Nifedipine ErNifedipine | 147 | $3,961 |
| Ezetimibe | 133 | $3,941 |
| Cilostazol | 162 | $3,254 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 19 | $3,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $38,208 | $405,710404 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Davenport
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Devika KirDavenport$11K
- Amit BahiaDavenport$8K
- Parth DesaiDavenport$5K
- Adnan YousafDavenport$4K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.